BIIB vs VRTX: fair value comparison
Biogen Inc. and Vertex Pharmaceuticals Incorporated · Updated 2026-10-19
BIIB currently screens as overvalued while VRTX screens as fairly valued. Within Healthcare, VRTX currently sits closer to the top of our ranking by discount to fair value. VRTX carries the stronger quality grade.
| BIIB | VRTX | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $225.71 | $510.08 |
| 12-month range | $147.86–$235.35 | $409.47–$557.96 |
| Rank by discount to fair value | #73 of 108 Healthcare | #70 of 108 Healthcare |
| Quality grade | B | A |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BIIB fair value analysis · VRTX fair value analysis